InsiderTrades.com logo
Ivan Hyep net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Ivan Hyep Biography and Net Worth

CFO of Bicara Therapeutics

Ivan Hyep brings over 15 years of experience in finance, strategy and operations. Prior to joining the founding executive team at Bicara in March 2021, Ivan was Head of Finance at MOMA Therapeutics and Director of Finance at Third Rock Ventures. Ivan began and spent the first decade of his career at Bain Capital in global private equity.

Ivan holds a Bachelor of Science degree in Finance from Bentley University and an MBA with High Honors from Boston University Questrom School of Business.

What is Ivan Hyep's net worth?

The estimated net worth of Ivan Hyep is at least $2.30 million as of January 22nd, 2026. Hyep owns 145,355 shares of Bicara Therapeutics stock worth more than $2,298,644 as of February 20th. This net worth approximation does not reflect any other assets that Hyep may own. Additionally, Hyep receives an annual salary of $597,500.00 as CFO at Bicara Therapeutics. Learn More about Ivan Hyep's net worth.

How old is Ivan Hyep?

Hyep is currently 40 years old. There are 4 older executives and no younger executives at Bicara Therapeutics. The oldest executive at Bicara Therapeutics is Dr. David Raben M.D., Chief Medical Officer, who is 61 years old. Learn More on Ivan Hyep's age.

What is Ivan Hyep's salary?

As the CFO of Bicara Therapeutics Inc., Hyep earns $597,500.00 per year. There are 2 executives that earn more than Hyep. The highest earning executive at Bicara Therapeutics is Mr. Ryan Cohlhepp Pharm.D., President, COO & Director, who commands a salary of $660,000.00 per year. Learn More on Ivan Hyep's salary.

How do I contact Ivan Hyep?

The corporate mailing address for Hyep and other Bicara Therapeutics executives is 116 Huntington Avenue, Suite 703, Boston, MA 02116, United States. Bicara Therapeutics can also be reached via phone at (617) 468-4219 and via email at [email protected]. Learn More on Ivan Hyep's contact information.

Has Ivan Hyep been buying or selling shares of Bicara Therapeutics?

Over the course of the past ninety days, Ivan Hyep has sold $34,158.30 in shares of Bicara Therapeutics stock. Most recently, Ivan Hyep sold 1,882 shares of the business's stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $18.15, for a transaction totalling $34,158.30. Following the completion of the sale, the chief financial officer now directly owns 145,355 shares of the company's stock, valued at $2,638,193.25. Learn More on Ivan Hyep's trading history.

Who are Bicara Therapeutics' active insiders?

Bicara Therapeutics' insider roster includes Ryan Cohlhepp (COO), Ivan Hyep (CFO), Claire Mazumdar (CEO), and David Raben (Insider). Learn More on Bicara Therapeutics' active insiders.

Are insiders buying or selling shares of Bicara Therapeutics?

In the last year, insiders at the sold shares 19 times. They sold a total of 242,456 shares worth more than $4,466,154.60. The most recent insider tranaction occured on January, 22nd when COO Ryan Cohlhepp sold 3,828 shares worth more than $69,286.80. Insiders at Bicara Therapeutics own 15.5% of the company. Learn More about insider trades at Bicara Therapeutics.

Information on this page was last updated on 1/22/2026.

Ivan Hyep Insider Trading History at Bicara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2026Sell1,882$18.15$34,158.30145,355View SEC Filing Icon  
11/24/2025Sell17,795$18.55$330,097.25145,355View SEC Filing Icon  
11/21/2025Sell605$18.15$10,980.75145,355View SEC Filing Icon  
10/9/2025Sell6,415$18.23$116,945.45145,355View SEC Filing Icon  
10/8/2025Sell5,627$18.21$102,467.67145,355View SEC Filing Icon  
10/7/2025Sell18,244$18.22$332,405.68145,355View SEC Filing Icon  
10/6/2025Sell6,514$18.17$118,359.38145,355View SEC Filing Icon  
See Full Table

Ivan Hyep Buying and Selling Activity at Bicara Therapeutics

This chart shows Ivan Hyep's buying and selling at Bicara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bicara Therapeutics Company Overview

Bicara Therapeutics logo
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $15.48
Low: $15.39
High: $16.68

50 Day Range

MA: $16.57
Low: $14.06
High: $18.48

2 Week Range

Now: $15.48
Low: $7.80
High: $19.71

Volume

1,171,906 shs

Average Volume

430,859 shs

Market Capitalization

$847.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A